This study is not accepting new patients

ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

a study on Bladder Cancer

Summary

Eligibility
for people ages 18-100 (full criteria)
Location
at UCSD
Dates
study started
Principal Investigator
by Aditya Bagrodia, MD (ucsd)

Description

Summary

This expanded access protocol is designed to provide Recombinant Mycobacterium BCG (rMBCG) to patients with Non-muscle invasive bladder cancer (NMIBC) who are eligible to receive TICE® BCG, may benefit from its use, and who are ineligible to participate in a clinical trial using rMBCG, or for other reasons cannot participate (eg, geographically unable to access a study site).

Keywords

NMIBC, Non-Muscle Invasive Bladder Neoplasms, rMBCG

Eligibility

For people ages 18-100

Participant Eligibility:

Women and men of all races and ethnic groups are eligible for this trial.

Inclusion Criteria and Contraindications:

Participants must meet the inclusion criteria and contraindications determined by the standards of their institution per the TICE BCG label. In BCG naïve subjects with NMIBC, enrollment should occur only if TICE BCG is unavailable.

Locations

  • UC San Diego Moores Cancer Center not accepting new patients
    La Jolla California 92093 United States
  • Saint John's Cancer Institute (Providence) not accepting new patients
    Santa Monica California 90404 United States
  • USC/ Norris Comprehensive Cancer Center not accepting new patients
    Los Angeles California 90033 United States

Lead Scientist at University of California Health

  • Aditya Bagrodia, MD (ucsd)
    Professor, Urology, Vc-health Sciences-schools. Authored (or co-authored) 282 research publications

Details

Status
not accepting new patients
Start Date
Sponsor
ImmunityBio, Inc.
ID
NCT06810141
Study Type
Expanded Access
Last Updated
Contact us about this trial